Creative Planning Boosts Stock Holdings in Innoviva, Inc. (NASDAQ:INVA)

Creative Planning raised its holdings in Innoviva, Inc. (NASDAQ:INVA) by 21.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,780 shares of the biotechnology company’s stock after purchasing an additional 4,669 shares during the period. Creative Planning’s holdings in Innoviva were worth $517,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. SageView Advisory Group LLC purchased a new position in shares of Innoviva in the first quarter worth about $1,555,000. Boston Partners grew its stake in Innoviva by 90.3% during the first quarter. Boston Partners now owns 391,456 shares of the biotechnology company’s stock valued at $5,966,000 after acquiring an additional 185,784 shares in the last quarter. O Shaughnessy Asset Management LLC grew its stake in Innoviva by 108.8% during the first quarter. O Shaughnessy Asset Management LLC now owns 73,066 shares of the biotechnology company’s stock valued at $1,114,000 after acquiring an additional 38,080 shares in the last quarter. Victory Capital Management Inc. grew its stake in Innoviva by 63.1% during the second quarter. Victory Capital Management Inc. now owns 135,755 shares of the biotechnology company’s stock valued at $2,226,000 after acquiring an additional 52,523 shares in the last quarter. Finally, BOKF NA lifted its position in Innoviva by 180.5% during the second quarter. BOKF NA now owns 46,377 shares of the biotechnology company’s stock valued at $761,000 after purchasing an additional 29,846 shares during the last quarter. Hedge funds and other institutional investors own 99.12% of the company’s stock.

Innoviva Trading Up 0.4 %

NASDAQ:INVA opened at $19.43 on Wednesday. The company has a fifty day moving average of $19.56 and a 200 day moving average of $17.73. Innoviva, Inc. has a 52 week low of $13.31 and a 52 week high of $20.37. The company has a quick ratio of 11.40, a current ratio of 12.70 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $1.22 billion, a P/E ratio of 11.78 and a beta of 0.57.

Wall Street Analyst Weigh In

INVA has been the subject of several research analyst reports. StockNews.com lowered shares of Innoviva from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Innoviva in a report on Tuesday, July 30th.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.